div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: JournalAgenthistolojiye sahipti Üç postoperatif ölüm vardl % 10 Metakron kanserli 40 hastanm birinci ve ikinci kanser te- davisi arasmdaki ortalama intervali 5 Yll 11 aydl src=https:reader036fdocumentpubreader036viewer20220816206104b9a914bfeb023a162d0ehtml5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: JournalAgenthistolojiye sahipti Üç postoperatif ölüm vardl % 10 Metakron kanserli 40 hastanm birinci ve ikinci kanser te- davisi arasmdaki ortalama intervali 5 Yll 11 aydl src=https:reader036fdocumentpubreader036viewer20220816206104b9a914bfeb023a162d0ehtml5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: JournalAgenthistolojiye sahipti Üç postoperatif ölüm vardl % 10 Metakron kanserli 40 hastanm birinci ve ikinci kanser te- davisi arasmdaki ortalama intervali 5 Yll 11 aydl src=https:reader036fdocumentpubreader036viewer20220816206104b9a914bfeb023a162d0ehtml5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: JournalAgenthistolojiye sahipti Üç postoperatif ölüm vardl % 10 Metakron kanserli 40 hastanm birinci ve ikinci kanser te- davisi arasmdaki ortalama intervali 5 Yll 11 aydl src=https:reader036fdocumentpubreader036viewer20220816206104b9a914bfeb023a162d0ehtml5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdiv